Savara Inc (NASDAQ:SVRA) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC cut its position in Savara Inc (NASDAQ:SVRA) by 11.7% during the fourth quarter, HoldingsChannel reports. The firm owned 59,049 shares of the company’s stock after selling 7,858 shares during the quarter. MetLife Investment Management LLC’s holdings in Savara were worth $181,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after purchasing an additional 365,959 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Savara by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock worth $8,549,000 after buying an additional 57,187 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in Savara during the 4th quarter worth about $8,151,000. Emerald Advisers LLC acquired a new position in shares of Savara during the 4th quarter worth about $7,161,000. Finally, Altium Capital Management LLC increased its holdings in shares of Savara by 0.3% in the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock valued at $4,848,000 after acquiring an additional 4,000 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Stock Up 5.2 %

Shares of NASDAQ SVRA opened at $3.22 on Friday. The stock has a market cap of $556.25 million, a PE ratio of -7.49 and a beta of 0.44. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.11. The business has a 50-day moving average price of $2.89 and a 200 day moving average price of $3.05. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. Equities research analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Savara in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.